Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization

Am J Cardiol. 2005 Mar 15;95(6):744-7. doi: 10.1016/j.amjcard.2004.11.026.

Abstract

The incidence of antiplatelet factor-4/heparin antibody formation in patients who receive contemporary doses of unfractionated heparin in the setting of percutaneous coronary revascularization is unknown. Also unknown is the ability of these antibodies to activate platelets or adversely affect clinical outcome in the absence of clinically recognized heparin-induced thrombocytopenia. To address these questions, we serially measured antiplatelet factor-4/heparin antibody levels and performed serotonin release assays in patients who underwent percutaneous coronary intervention. Correlations were then made across antibody induction, heparin exposure, and clinical outcome at 6 months.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angina Pectoris / immunology*
  • Angina Pectoris / mortality
  • Angina Pectoris / therapy
  • Angioplasty, Balloon, Coronary*
  • Antibody Formation / drug effects
  • Antibody Formation / immunology*
  • Coronary Disease / immunology*
  • Coronary Disease / mortality
  • Coronary Disease / therapy
  • Female
  • Follow-Up Studies
  • Heparin / administration & dosage
  • Heparin / adverse effects
  • Heparin / immunology*
  • Humans
  • Immune Complex Diseases / chemically induced
  • Immune Complex Diseases / immunology
  • Immune Complex Diseases / mortality
  • Male
  • Middle Aged
  • Myocardial Infarction / immunology*
  • Myocardial Infarction / mortality
  • Myocardial Infarction / therapy
  • Platelet Activation / drug effects
  • Platelet Activation / immunology
  • Platelet Factor 4 / immunology*
  • Purpura, Thrombocytopenic, Idiopathic / chemically induced
  • Purpura, Thrombocytopenic, Idiopathic / diagnosis
  • Purpura, Thrombocytopenic, Idiopathic / immunology
  • Purpura, Thrombocytopenic, Idiopathic / mortality
  • Recurrence
  • Risk Factors
  • Serotonin / blood
  • Survival Rate

Substances

  • Serotonin
  • Platelet Factor 4
  • Heparin